MedaSystems, a Menlo Park, CA-based provider of a SaaS platform for expanded access (EA) and investigator-initiated studies (IIS), raised an additional undisclosed amount in Seed funding.
Backers included Debiopharm Innovation Fund, Nina Capital, and Young Sohn.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Brian Irwin, MedaSystems provides a SaaS platform that automates and streamlines expanded access and investigator-initiated study processes, enabling faster responses to treatment inquiries and enhancing real-world data capture for regulatory submissions. The company also offers a centralized hub for healthcare providers, pharmaceutical companies, and regulatory partners to collaborate seamlessly. With it, physicians can manage patient requests in-app, working alongside their teams and pharmacists, while life sciences companies can integrate external partners, such as contract research organizations (CROs), to ensure coordinated communication, workflow automation, and expedited treatment delivery.
FinSMEs
05/03/2025